TY - JOUR
T1 - Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality
T2 - Collaborative analysis of 32 prospective studies
AU - The Lp-PLA Studies Collaboration
AU - Thompson, Alexander
AU - Gao, Pei
AU - Orfei, Lia
AU - Watson, Sarah
AU - Di Angelantonio, Emanuele
AU - Kaptoge, Stephen
AU - Ballantyne, Christie
AU - Cannon, Christopher P.
AU - Criqui, Michael
AU - Cushman, Mary
AU - Hofman, Albert
AU - Packard, Chris
AU - Thompson, Simon G.
AU - Collins, Rory
AU - Danesh, John
AU - Willeit, Johann
AU - Kiechl, Stefan
AU - Wiedermann, Christian
AU - Psaty, Bruce
AU - Furberg, Curt
AU - Khaw, Kay Tee
AU - Sandhu, Manjinder
AU - Benjamin, Emelia J.
AU - Vasan, Ramachandran S.
AU - Schnabel, Renate B.
AU - Oldgren, Jonas
AU - Rossi, Gian Paolo
AU - Cesari, Maurizio
AU - Lenzini, Livia
AU - Zanchetta, Mario
AU - James, Stefan K.
AU - Rimm, Eric
AU - Hatoum, Ida
AU - Anderson, Jeffrey L.
AU - May, Heidi T.
AU - Horne, Benjamin D.
AU - Carlquist, John F.
AU - Muhlestein, Joseph B.
AU - Koenig, Wolfgang
AU - Brenner, Hermann
AU - Rothenbacher, Dietrich
AU - März, Winfried
AU - Böhm, Bernhard
AU - Winkelmann, Bernhard R.
AU - Winkler, Karl
AU - Berglund, Goran
AU - Persson, Margaretha
AU - Roger, Veronique
AU - Gerber, Yariv
AU - Berger, Peter B.
N1 - Funding Information:
The independent academic Lp-PLA 2 Studies Collaboration coordinating centre has been supported by specific grants from the UK Medical Research Council ( G0601284 ) and GlaxoSmithKline, and is underpinned by a programme grant from the British Heart Foundation ( RG/08/014 ). Alexander Thompson and Emanuele Di Angelantonio were supported by UK Medical Research Council doctoral training grants. A variety of sources have supported recruitment, follow-up, and laboratory measurements in the 32 studies contributing to the Lp-PLA 2 Studies Collaboration. Investigators of several of these studies have contributed to a list naming some of these funding sources, which can be found at http://www.phpc.cam.ac.uk/ceu/lsc . Pierre Jacob and Clément Pravin provided statistical support. Hannah Sneath, Angela Harper, and Karina Prasad provided administrative support. Mary Cushman provided limited tabular data on Lp-PLA 2 reproducibility on behalf of the Multi-Ethnic Study of Atherosclerosis (MESA) investigators.
Funding Information:
The independent academic Lp-PLA2 Studies Collaboration coordinating centre has been supported by specific grants from the UK Medical Research Council (G0601284) and GlaxoSmithKline, and is underpinned by a programme grant from the British Heart Foundation (RG/08/014). Alexander Thompson and Emanuele Di Angelantonio were supported by UK Medical Research Council doctoral training grants. A variety of sources have supported recruitment, follow-up, and laboratory measurements in the 32 studies contributing to the Lp-PLA2 Studies Collaboration. Investigators of several of these studies have contributed to a list naming some of these funding sources, which can be found at http://www.phpc.cam.ac.uk/ceu/lsc. Pierre Jacob and Cl?ment Pravin provided statistical support. Hannah Sneath, Angela Harper, and Karina Prasad provided administrative support. Mary Cushman provided limited tabular data on Lp-PLA2 reproducibility on behalf of the Multi-Ethnic Study of Atherosclerosis (MESA) investigators.
Publisher Copyright:
© 2010, Lancet Publishing Group. All rights reserved.
PY - 2010
Y1 - 2010
N2 - Background Lipoprotein-associated phospholipase A2 (Lp-PLA2), an inflammatory enzyme expressed in atherosclerotic plaques, is a therapeutic target being assessed in trials of vascular disease prevention. We investigated associations of circulating Lp-PLA2 mass and activity with risk of coronary heart disease, stroke, and mortality under different circumstances. Methods With use of individual records from 79 036 participants in 32 prospective studies (yielding 17 722 incident fatal or non-fatal outcomes during 474 976 person-years at risk), we did a meta-analysis of within-study regressions to calculate risk ratios (RRs) per 1 SD higher value of Lp-PLA2 or other risk factor. The primary outcome was coronary heart disease. Findings Lp-PLA2 activity and mass were associated with each other (r=0·51, 95% CI 0·47-0·56) and proatherogenic lipids. We noted roughly log-linear associations of Lp-PLA2 activity and mass with risk of coronary heart disease and vascular death. RRs, adjusted for conventional risk factors, were: 1·10 (95% CI 1·05-1·16) with Lp-PLA2 activity and 1·11 (1·07-1·16) with Lp-PLA2 mass for coronary heart disease; 1·08 (0·97-1·20) and 1·14 (1·02-1·27) for ischaemic stroke; 1·16 (1·09-1·24) and 1·13 (1·05-1·22) for vascular mortality; and 1·10 (1·04-1·17) and 1·10 (1·03-1·18) for non-vascular mortality, respectively. RRs with Lp-PLA2 did not differsignificantly in people with and without initial stable vascular disease, apart from for vascular death with Lp-PLA2 mass. Adjusted RRs for coronary heart disease were 1·10 (1·02-1·18) with non-HDL cholesterol and 1·10 (1·00-1·21) with systolic blood pressure. Interpretation Lp-PLA2 activity and mass each show continuous associations with risk of coronary heart disease, similar in magnitude to that with non-HDL cholesterol or systolic blood pressure in this population. Associations of Lp-PLA2 mass and activity are not exclusive to vascular outcomes, and the vascular associations depend at least partly on lipids.
AB - Background Lipoprotein-associated phospholipase A2 (Lp-PLA2), an inflammatory enzyme expressed in atherosclerotic plaques, is a therapeutic target being assessed in trials of vascular disease prevention. We investigated associations of circulating Lp-PLA2 mass and activity with risk of coronary heart disease, stroke, and mortality under different circumstances. Methods With use of individual records from 79 036 participants in 32 prospective studies (yielding 17 722 incident fatal or non-fatal outcomes during 474 976 person-years at risk), we did a meta-analysis of within-study regressions to calculate risk ratios (RRs) per 1 SD higher value of Lp-PLA2 or other risk factor. The primary outcome was coronary heart disease. Findings Lp-PLA2 activity and mass were associated with each other (r=0·51, 95% CI 0·47-0·56) and proatherogenic lipids. We noted roughly log-linear associations of Lp-PLA2 activity and mass with risk of coronary heart disease and vascular death. RRs, adjusted for conventional risk factors, were: 1·10 (95% CI 1·05-1·16) with Lp-PLA2 activity and 1·11 (1·07-1·16) with Lp-PLA2 mass for coronary heart disease; 1·08 (0·97-1·20) and 1·14 (1·02-1·27) for ischaemic stroke; 1·16 (1·09-1·24) and 1·13 (1·05-1·22) for vascular mortality; and 1·10 (1·04-1·17) and 1·10 (1·03-1·18) for non-vascular mortality, respectively. RRs with Lp-PLA2 did not differsignificantly in people with and without initial stable vascular disease, apart from for vascular death with Lp-PLA2 mass. Adjusted RRs for coronary heart disease were 1·10 (1·02-1·18) with non-HDL cholesterol and 1·10 (1·00-1·21) with systolic blood pressure. Interpretation Lp-PLA2 activity and mass each show continuous associations with risk of coronary heart disease, similar in magnitude to that with non-HDL cholesterol or systolic blood pressure in this population. Associations of Lp-PLA2 mass and activity are not exclusive to vascular outcomes, and the vascular associations depend at least partly on lipids.
UR - http://www.scopus.com/inward/record.url?scp=77951605907&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951605907&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(10)60319-4
DO - 10.1016/S0140-6736(10)60319-4
M3 - Article
C2 - 20435228
AN - SCOPUS:77951605907
SN - 0140-6736
VL - 375
SP - 1536
EP - 1544
JO - The Lancet
JF - The Lancet
IS - 9725
ER -